Christina Ochsenbauer

List of Publications by Year
in descending order

50	3,035	236925 25	182427 51
papers	citations	h-index	g-index

51	51	51	4188
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Phenotypic properties of transmitted founder HIV-1. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 6626-6633.	7.1	379
2	Generation of Transmitted/Founder HIV-1 Infectious Molecular Clones and Characterization of Their Replication Capacity in CD4 T Lymphocytes and Monocyte-Derived Macrophages. Journal of Virology, 2012, 86, 2715-2728.	3.4	291
3	Global Panel of HIV-1 Env Reference Strains for Standardized Assessments of Vaccine-Elicited Neutralizing Antibodies. Journal of Virology, 2014, 88, 2489-2507.	3.4	274
4	An HIV-1 gp120 Envelope Human Monoclonal Antibody That Recognizes a C1 Conformational Epitope Mediates Potent Antibody-Dependent Cellular Cytotoxicity (ADCC) Activity and Defines a Common ADCC Epitope in Human HIV-1 Serum. Journal of Virology, 2011, 85, 7029-7036.	3.4	210
5	Relative resistance of HIV-1 founder viruses to control by interferon-alpha. Retrovirology, 2013, 10, 146.	2.0	183
6	Replication competent molecular clones of HIV-1 expressing Renilla luciferase facilitate the analysis of antibody inhibition in PBMC. Virology, 2010, 408, 1-13.	2.4	169
7	Macrophage Infection via Selective Capture of HIV-1-Infected CD4+ T Cells. Cell Host and Microbe, 2014, 16, 711-721.	11.0	143
8	HIV-1 Neutralizing Antibody Signatures and Application to Epitope-Targeted Vaccine Design. Cell Host and Microbe, 2019, 25, 59-72.e8.	11.0	124
9	Phenotypic and Functional Profile of HIV-Inhibitory CD8 T Cells Elicited by Natural Infection and Heterologous Prime/Boost Vaccination. Journal of Virology, 2010, 84, 4998-5006.	3.4	110
10	Multispecific anti-HIV duoCAR-T cells display broad in vitro antiviral activity and potent in vivo elimination of HIV-infected cells in a humanized mouse model. Science Translational Medicine, 2019, 11, .	12.4	104
11	In Vivo Activation of Human NK Cells by Treatment with an Interleukin-15 Superagonist Potently Inhibits Acute In Vivo HIV-1 Infection in Humanized Mice. Journal of Virology, 2015, 89, 6264-6274.	3.4	78
12	Bispecific antibodies directed to CD4 domain 2 and HIV envelope exhibit exceptional breadth and picomolar potency against HIV-1. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 13540-13545.	7.1	73
13	Neutrophil extracellular traps prevent HIV infection in the female genital tract. Mucosal Immunology, 2018, 11, 1420-1428.	6.0	72
14	Mass Cytometric Analysis of HIV Entry, Replication, and Remodeling in Tissue CD4+ T Cells. Cell Reports, 2017, 20, 984-998.	6.4	66
15	Incomplete Downregulation of CD4 Expression Affects HIV-1 Env Conformation and Antibody-Dependent Cellular Cytotoxicity Responses. Journal of Virology, 2018, 92, .	3.4	56
16	Association of HIV-1 Envelope-Specific Breast Milk IgA Responses with Reduced Risk of Postnatal Mother-to-Child Transmission of HIV-1. Journal of Virology, 2015, 89, 9952-9961.	3.4	55
17	Mucosal stromal fibroblasts markedly enhance HIV infection of CD4+ T cells. PLoS Pathogens, 2017, 13, e1006163.	4.7	51
18	Neutralization Takes Precedence Over IgG or IgA Isotype-related Functions in Mucosal HIV-1 Antibody-mediated Protection. EBioMedicine, 2016, 14, 97-111.	6.1	47

#	Article	IF	Citations
19	Potent Functional Antibody Responses Elicited by HIV-I DNA Priming and Boosting with Heterologous HIV-1 Recombinant MVA in Healthy Tanzanian Adults. PLoS ONE, 2015, 10, e0118486.	2.5	42
20	Optimization and validation of a neutralizing antibody assay for HIV-1 in A3R5 cells. Journal of Immunological Methods, 2014, 409, 147-160.	1.4	39
21	Uterine Epithelial Cell Regulation of DC-SIGN Expression Inhibits Transmitted/Founder HIV-1 Trans Infection by Immature Dendritic Cells. PLoS ONE, 2010, 5, e14306.	2.5	33
22	Mice Transgenic for CD4-Specific Human CD4, CCR5 and Cyclin T1 Expression: A New Model for Investigating HIV-1 Transmission and Treatment Efficacy. PLoS ONE, 2013, 8, e63537.	2.5	31
23	PotentIn VivoNK Cell-Mediated Elimination of HIV-1-Infected Cells Mobilized by a gp120-Bispecific and Hexavalent Broadly Neutralizing Fusion Protein. Journal of Virology, 2017, 91, .	3.4	31
24	Casp8p41 generated by HIV protease kills CD4 T cells through direct Bak activation. Journal of Cell Biology, 2014, 206, 867-876.	5.2	28
25	Development of a luciferase based viral inhibition assay to evaluate vaccine induced CD8 T-cell responses. Journal of Immunological Methods, 2014, 409, 161-173.	1.4	28
26	The transcriptome of HIV-1 infected intestinal CD4+ T cells exposed to enteric bacteria. PLoS Pathogens, 2017, 13, e1006226.	4.7	28
27	Optimized ReplicatingRenillaLuciferase Reporter HIV-1 Utilizing Novel Internal Ribosome Entry Site Elements for Native Nef Expression and Function. AIDS Research and Human Retroviruses, 2015, 31, 1278-1296.	1.1	26
28	New virologic reagents for neutralizing antibody assays. Current Opinion in HIV and AIDS, 2009, 4, 418-425.	3.8	24
29	Mucosal Tissue Tropism and Dissemination of HIV-1 Subtype B Acute Envelope-Expressing Chimeric Virus. Journal of Virology, 2013, 87, 890-899.	3.4	23
30	Primary HIV-1 Strains Use Nef To Downmodulate HLA-E Surface Expression. Journal of Virology, 2019, 93, .	3.4	21
31	Antibody-Dependent Cellular Cytotoxicity (ADCC)-Mediating Antibodies Constrain Neutralizing Antibody Escape Pathway. Frontiers in Immunology, 2019, 10, 2875.	4.8	20
32	Longitudinal bioluminescent imaging of HIV-1 infection during antiretroviral therapy and treatment interruption in humanized mice. PLoS Pathogens, 2019, 15, e1008161.	4.7	19
33	Rectal tissue and vaginal tissue from intravenous VRC01 recipients show protection against ex vivo HIV-1 challenge. Journal of Clinical Investigation, 2021, 131, .	8.2	17
34	Sex-specific innate immune selection of HIV-1 in utero is associated with increased female susceptibility to infection. Nature Communications, 2020, 11, 1767.	12.8	15
35	Synergy in monoclonal antibody neutralization of HIV-1 pseudoviruses and infectious molecular clones. Journal of Translational Medicine, 2014, 12, 346.	4.4	14
36	The Vaginal Acquisition and Dissemination of HIV-1 Infection in a Novel Transgenic Mouse Model Is Facilitated by Coinfection with Herpes Simplex Virus 2 and Is Inhibited by Microbicide Treatment. Journal of Virology, 2015, 89, 9559-9570.	3.4	13

#	Article	IF	Citations
37	Superior Efficacy of a Human Immunodeficiency Virus Vaccine Combined with Antiretroviral Prevention in Simian-Human Immunodeficiency Virus-Challenged Nonhuman Primates. Journal of Virology, 2016, 90, 5315-5328.	3.4	12
38	CD4 regulatory T cells augment HIV-1 expression of polarized M1 and M2 monocyte derived macrophages. Virology, 2017, 504, 79-87.	2.4	12
39	Characterization of immune cells and infection by <scp>HIV</scp> in human ovarian tissues. American Journal of Reproductive Immunology, 2017, 78, e12687.	1.2	12
40	Detection of the HIV-1 Accessory Proteins Nef and Vpu by Flow Cytometry Represents a New Tool to Study Their Functional Interplay within a Single Infected CD4 ⁺ T Cell. Journal of Virology, 2022, 96, jvi0192921.	3.4	10
41	Buprenorphine Increases HIV-1 Infection In Vitro but Does Not Reactivate HIV-1 from Latency. Viruses, 2021, 13, 1472.	3.3	8
42	High-Throughput Humanized Mouse Models for Evaluation of HIV-1 Therapeutics and Pathogenesis. Methods in Molecular Biology, 2016, 1354, 221-235.	0.9	7
43	Selection of HIV Envelope strains for standardized assessments of vaccine-elicited antibody-dependent cellular cytotoxicity (ADCC)-mediating antibodies. Journal of Virology, 2021, , JVI0164321.	3.4	7
44	ADCC-mediating non-neutralizing antibodies can exert immune pressure in early HIV-1 infection. PLoS Pathogens, 2021, 17, e1010046.	4.7	6
45	Breadth of CD8 T-cell mediated inhibition of replication of diverse HIV-1 transmitted-founder isolates correlates with the breadth of recognition within a comprehensive HIV-1 Gag, Nef, Env and Pol potential T-cell epitope (PTE) peptide set. PLoS ONE, 2021, 16, e0260118.	2.5	6
46	Accumulated mutations by 6 months of infection collectively render transmitted/founder HIV-1 significantly less fit. Journal of Infection, 2020, 80, 210-218.	3.3	5
47	Elevated HIV Infection of CD4 T Cells in MRKAd5 Vaccine Recipients Due to CD8 T Cells Targeting Adapted Epitopes. Journal of Virology, 2021, 95, e0016021.	3.4	4
48	Characterization of Near Full-Length Transmitted/Founder HIV-1 Subtype D and A/D Recombinant Genomes in a Heterosexual Ugandan Population (2006â€“2011). Viruses, 2022, 14, 334.	3.3	4
49	Innate immune regulation in HIV latency models. Retrovirology, 2022, 19, .	2.0	3
50	Characterization of Simian Immunodeficiency Virus Variants Anatomically Compartmentalized in Plasma and Milk in Chronically Infected African Green Monkeys. Journal of Virology, 2016, 90, 8795-8808.	3.4	1